Here are a few analogies for AirSculpt Technologies (AIRS):

• Like Ideal Image for body contouring.
• Like LasikPlus for cosmetic fat removal procedures.
• Like Drybar for specialized cosmetic fat removal services.

• AirSculpt Procedure: A minimally invasive custom body contouring procedure that removes unwanted fat.
• Power BBL: A Brazilian butt lift procedure that utilizes the patient's own fat cells for enhancement.
• Up a Cup: A breast enhancement procedure that uses the patient's own fat cells.
• Hip Flip: An hourglass contouring procedure that sculpts the hips using fat transfer.

AirSculpt Technologies (AIRS) sells primarily to individuals rather than other companies. Based on the services described, its customers are individuals seeking cosmetic body contouring procedures. The categories of customers it serves can be described as follows:

1. Individuals seeking targeted fat reduction: These customers are looking to remove unwanted fat from specific areas of their body using minimally invasive procedures like AirSculpt.
2. Individuals seeking natural body augmentation and enhancement: This category includes customers who desire to enhance or reshape specific body parts, such as breasts, buttocks, or hips, by utilizing their own fat cells through procedures like the Power BBL, Up a Cup, or Hip Flip.
3. Individuals seeking overall body sculpting and aesthetic improvement: These customers are generally looking for a more comprehensive transformation of their physique, often combining fat removal and transfer techniques to achieve a desired contour and improve their overall body image and confidence.

Yogi Jashnani, Chief Executive Officer

Mr. Jashnani has served as Chief Executive Officer since January 7, 2025. He has over 20 years of experience in the aesthetics, retail, and finance industries. Prior to joining AirSculpt Technologies, he was Chief Revenue Officer for Sky Zone. From 2019 through 2023, he served as Chief Commercial Officer of Ideal Image. Earlier, from fiscal 2017 through 2019, he was SVP, Marketing, Insights and Analytics of Advance Auto Parts, and before that, Vice President at Capital One.

Michael Arthur, Chief Financial Officer

Mr. Arthur oversees all financial strategy and operations for AirSculpt Technologies, including accounting, FP&A, treasury, and capital markets. He previously served as CFO of Inspirato Incorporated, where he also held senior finance leadership roles including Senior Vice President of Finance and Vice President of FP&A and Treasury. Earlier in his career, Mr. Arthur held finance and strategy roles at CSC Generation and VF Corporation and began his career in PwC's Financial Services practice.

Brian Stetter, Chief Digital Officer

Mr. Stetter has served as Chief Digital Officer for AirSculpt since October 2024, leading the marketing and digital technology teams. He has over 20 years of experience in marketing across multiple industries. Most recently, he was Chief Marketing Officer for Walker Advertising and previously served as VP, Performance Marketing for Ideal Image.

Nicole Soler, Chief Sales Officer

Ms. Soler drives sales strategy, revenue optimization, and client engagement at AirSculpt Technologies, leading large, cross-functional teams. She brings over 12 years of executive leadership experience and 14 years in consultative and value-based selling, during which she has built, scaled, and optimized high-performing sales organizations across various industries.

Here are the key risks to AirSculpt Technologies (AIRS):

1. Patient Safety, Malpractice, and Reputational/Regulatory Risks: AirSculpt Technologies faces significant risks related to patient safety, potential medical malpractice claims, and regulatory scrutiny. The nature of cosmetic procedures inherently carries a risk of adverse outcomes for patients, which can lead to lawsuits and litigation from unsatisfied clients. There have been specific allegations of severe injuries, including patient death and permanent disfigurement, as well as claims of doctors with questionable credentials, revoked licenses, and misleading advertising practices such as employees posing as patients or undisclosed paid influencer reviews. Furthermore, the medical aesthetics industry operates within a complex and increasingly scrutinized regulatory environment, encompassing healthcare laws, facility licensing, medical oversight, and restrictions on advertising claims. Non-compliance with these regulations can expose the company to significant legal and financial risks, severely impacting its brand and operational viability.
2. Revenue Softness, Challenges in Executing Growth Strategies, and Market Demand Volatility: The company has experienced ongoing revenue softness, a lowered 2025 outlook, and significant misses in recent quarterly earnings forecasts. This is attributed, in part, to consumer hesitancy in making higher-consideration purchases and uncertain demand for new services, including those targeting GLP-1 users. AirSculpt Technologies' ability to reverse these trends depends heavily on the effective execution of its cost-saving initiatives, operational consolidation, and new revenue growth strategies. Factors like inflation and broader economic pressures can also lead consumers to postpone discretionary spending, further impacting procedure volume and overall revenue. The company's negative operating margin and free cash flow, along with tight liquidity and at-risk interest coverage, highlight the financial challenges associated with these revenue and growth issues.
3. Intense Competition and Lack of Strong Differentiated Advantage: The body contouring and fat reduction market is highly competitive, with numerous offerings from various companies, including both surgical and non-surgical methods. AirSculpt Technologies' business model is described as having a "low tech nature" with no patent protection for its devices, meaning its competitive advantage largely relies on the strength of its brand rather than proprietary technology. This competitive landscape makes it challenging for AirSculpt to maintain market share, achieve scalable growth, and defend against new entrants or evolving aesthetic technologies.

AirSculpt Technologies (symbol: AIRS) operates in the aesthetic body contouring market, focusing on minimally invasive fat removal and fat transfer procedures in the United States. The addressable markets for their main products and services are significant.

Fat Removal Procedures (Custom Body Contouring / Minimally Invasive Fat Reduction)

The market for non-invasive fat reduction in the U.S. is valued at approximately USD 1.8 billion. This market, which aligns with AirSculpt's minimally invasive fat removal procedures, is projected to reach USD 1.83 billion in North America by 2033, growing from USD 0.65 billion in 2025 at a compound annual growth rate (CAGR) of 13.87% from 2025 to 2033. North America is a dominant region in the non-invasive fat reduction market.

Fat Transfer Procedures (including Power BBL, Up a Cup, Hip Flip)

For fat transfer procedures, often referred to as autologous fat grafting, the global market was valued at US$ 202.4 million in 2024 and is expected to reach US$ 375.3 million by 2033, growing at a CAGR of 7.1%. North America is the leading regional market for autologous fat grafting in terms of revenue share.

Specifically for buttock augmentation, which includes procedures like the Brazilian Butt Lift (BBL) offered by AirSculpt, the global market is expected to reach USD 6.6 billion by 2028, growing at a CAGR of 22.0% from 2021 to 2028. North America dominates the buttock augmentation market. In the U.S., a significant number of buttock augmentation procedures are performed annually; for instance, the American Society of Aesthetic Plastic Surgeons (ASAPS) reported 61,387 buttock augmentations in 2021.

AirSculpt Technologies (symbol: AIRS) is expected to drive future revenue growth over the next 2-3 years through several key initiatives:

1. Expansion to New Markets and Centers: AirSculpt Technologies continues to open new body contouring centers. For example, the company opened its 32nd location in White Plains, NY, in December 2024 and its 30th location in Deerfield, IL, in September 2024. While the London center was closed in Q3 2025, the company stated its intention to focus resources on North American locations where it sees significant opportunity. This ongoing domestic expansion is a key driver.
2. Launch and Growth of New Products and Services: The company is introducing and expanding specialized procedures. This includes the AirSculpt+ skin tightening procedure, which combines fat removal with Renuvion® technology and is being offered in new and existing centers. Additionally, AirSculpt Lift, a minimally invasive facial fat transfer procedure, was added to the Scottsdale location in March 2024 and has been popular in other markets.
3. Development of Offerings for GLP-1 Users: AirSculpt Technologies began piloting new services in Q2 2025, specifically focusing on skin tightening that addresses the skin laxity associated with the use of GLP-1 medications. The CEO highlighted this as a "broader market opportunity ahead driven by the structural shift in the aesthetics space due to GLP-1 use."
4. Enhanced Go-to-Market Processes and Customer Experience Initiatives: The company is implementing "transformation initiatives" and "elevated go-to-market processes" aimed at improving customer acquisition and experience. These strategies include optimizing marketing efforts, refining sales processes, and expanding financing options to provide greater flexibility for consumers, which are expected to accelerate comparable sales improvement.

Share Issuance

• AirSculpt Technologies completed an Initial Public Offering (IPO) in October 2021, issuing 2,173,913 shares as part of a larger offering of 7,000,000 shares at $11.00 per share.
• In June 2025, the company launched an underwritten public offering of 3,160,000 shares of its common stock.
• This June 2025 offering was priced at $3.80 per share, generating $12.0 million in proceeds for the company before expenses.

Inbound Investments

• Vesey Street Capital Partners, a significant stockholder, indicated interest in purchasing up to $4 million in shares during the June 2025 public offering.
• As of March 2026, institutional investors and hedge funds held approximately 91.54% of the company's stock.
• Several institutional investors, including Aristides Capital LLC, Virtu Financial LLC, XTX Topco Ltd, and Caitong International Asset Management Co. Ltd, bought new stakes or increased their holdings in AirSculpt Technologies during the fourth quarter of 2025.

Capital Expenditures

• AirSculpt Technologies reported $180K in capital expenditures in Q3 2025, representing a 32.1% decrease from the previous quarter.
• In Q3 2025, capital expenditures totaled $14.0M, which largely consumed the $11.3M generated from operating cash flow, resulting in a negative free cash flow of -$2.7M.